The Effect of Statins on Levels of Dehydroepiandrosterone (DHEA) in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
Song Yang, Yuan-Yuan Gu, Fei Jing, Chun-Xiao Yu, Qing-Bo Guan
Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China (mainland)
Med Sci Monit 2019; 25:590-597
Available online: 2019-01-20
Currently, statins are used to treat polycystic ovary syndrome (PCOS). This systematic review and meta-analysis aimed to investigate the effect of statins on serum or plasma levels of dehydroepiandrosterone (DHEA) in women with PCOS.
MATERIAL AND METHODS: Databases that were searched included PubMed, Embase, and the Cochrane Library from their inception to August of 2018. Published randomized controlled trials (RCTs) were identified that evaluated the impact of statins on plasma DHEA levels in women with PCOS. The Cochrane risk of bias tool was used to assess the quality of the included RCTs. A random-effects model was used to analyze the pooled results.
RESULTS: Meta-analysis was performed on data from ten published studies that included 735 patients and showed that statin treatment could significantly reduce plasma DHEA levels when compared with controls (SMD, –0.43; 95% CI, –0.81–0.06; p=0.02; I²=82%). Statins were significantly more effective than placebo in reducing the levels of DHEAs. Subgroup analysis based on statin type showed that atorvastatin significantly reduced DHEA levels (SMD, –0.63; 95% CI, –1.20 – –0.05; p=0.03; I²=38%) but simvastatin did not significantly reduce DHEA levels (SMD: –0.14; 95% CI, –0.49–0.28; p=0.43; I²=77%). Subgroup analysis based on duration of treatment showed no significant difference between 12 weeks of statin treatment (SMD, –0.61; 95% CI, –1.23–0.02; p=0.06; I²=85%) and 24 weeks (SMD, –0.34; 95% CI –0.95–0.28; p=0.29; I²=83%).
CONCLUSIONS: Meta-analysis showed that statins significantly reduced the levels of DHEA when compared with placebo in patients with PCOS.
Keywords: Dehydroepiandrosterone Sulfate, Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors, meta-analysis, Polycystic Ovary Syndrome